bioRxivMicrobiology
Remdesivir-Ivermectin combination displays synergistic interaction with improved in vitro antiviral activity against SARS-CoV-2
L. Jeffreys, S. H. Pennington, J. Duggan, C. H. Caygill, R. C. Lopeman, A. Breen, J. Jinks, A. Ardrey, S. Donnellan, E. I. Patterson, G. I. Hughes, W. D. Hong, P. M. O'Neill, G. Aljayyoussi, A. Owen, S. A. Ward, G. A. Biagini
Abstract
A key element for the prevention and management of COVID-19 is the development of effective therapeutics. Drug combination strategies of repurposed drugs offer several advantages over monotherapies, including the potential to achieve greater efficacy, the potential to increase the therapeutic index of drugs and the potential to reduce the emergence of drug resistance. Here, we report on the in vitro synergistic interaction between two FDA approved drugs, remdesivir and ivermectin resulting in enhanced antiviral activity against SARS-CoV-2. These findings warrant further investigations into the clinical potential of this combination, together with studies to define the underlying mechanism.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Discovery of Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 In Vitro
T. Bobrowski, L. Chen, … E. N. Muratov·bioRxiv·Jun 29, 2020
- Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro
U. Rescher, S. Schloer, … S. Ludwig·bioRxiv·Oct 16, 2020
- Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells
X. Nguyenla, E. Wehri, … J. Schaletzky·bioRxiv·Sep 18, 2020
- Combination of the parent analogue of Remdesivir (GS-441524) and Molnupiravir results in a markedly potent antiviral effect in SARS-CoV-2 infected Syrian hamsters
R. Abdelnabi, P. Maes, … J. Neyts·bioRxiv·Oct 13, 2022
- Simeprevir suppresses SARS-CoV-2 replication and synergizes with remdesivir
H. S. Lo, K. P. Y. Hui, … W.-L. Ng·ACS Central SciencePeer-reviewed·Apr 15, 2021
- The FDA-approved drug cobicistat synergizes with remdesivir to inhibit SARS-CoV-2 replication
I. L. Shytaj, M. Fares, … M. Lusic·bioRxiv·Mar 9, 2021